Remove business executive-pay-bonuses
article thumbnail

Gender Pay Gap Backslides Within European Healthcare Industry

Pharma Marketing Network

With input from more than 50,000 employees at 180 companies, the data show that the median pay gap increased from 11.5 The report data indicates Sweden, Ireland, Netherlands, and Portugal have spearheaded an improvement in the gender pay gap since the 2021 report. percent to 14.4 percent in the past two years. “

article thumbnail

When £17m isn’t enough: FTSE firms plead to pay bosses millions more

The Guardian - Pharmaceutical Industry

Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier There was a sharp intake of breath last month when the pharmaceuticals group AstraZeneca cemented chief executive Pascal Soriot’s position as the best-paid FTSE 100 boss with a £17m pay package , up from £15.3m

Packaging 117
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AstraZeneca CEO Pascal Soriot’s £17m pay package under fire

The Guardian - Pharmaceutical Industry

Governance thinktank asks whether he has earned a hundred times that of many of his employees AstraZeneca’s chief executive, Pascal Soriot , received a pay package of nearly £17m last year, cementing his position as one of the best-paid FTSE 100 bosses as he drew criticism from corporate governance experts. Continue reading.

article thumbnail

AstraZeneca promises dividend rise hours before vote on boss’s £19m pay deal

The Guardian - Pharmaceutical Industry

pay boost Shareholders at AstraZeneca are in line for a 7% increase in dividends this year as the pharmaceutical company attempts to garner support for a pay deal worth up to £19m for its boss, Pascal Soriot. Drugmaker announces 7% increase as it seeks to garner support for Pascal Soriot’s £1.8m

article thumbnail

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca | Nils Prately

The Guardian - Pharmaceutical Industry

package opens door to likelihood of US-style executive pay elsewhere Is Pascal Soriot, the chief executive of AstraZeneca, “massively underpaid”, as the chief investment officer of Florida-based GQG Partners, one of the company’s big shareholders, argued this week? Despite rebellion, approval of £18.7m Well, of course he’s not.